KBL382 / KoBioLabs - LARVOL DELTA

Synergistic Modulation of the Gut-Brain-Immune Axis by a Dual Lactobacillus Combination in a Murine IBS Model. (PubMed, J Microbiol Biotechnol) - "Here, we demonstrate that oral co-administration of Lactobacillus paracasei KBL382 and Lactobacillus plantarum KBL396 synergistically ameliorates IBS-like symptoms in a zymosan-induced mouse model...Importantly, therapeutic effects were preserved in microbiota-depleted mice, demonstrating a microbiota-independent, host-targeted mechanism. These findings demonstrate that defined Lactobacillus strains synergistically modulate neuroimmune pathways via bioactive macromolecules, offering a host-directed strategy for managing the multifactorial symptoms of IBS."

Journal • Preclinical • Gastrointestinal Disorder • Inflammation • Mood Disorders • Mucositis • Psychiatry • IL10 • IL6R • MYD88

Treatment of Lactobacillus paracasei KBL382 modulates intestinal inflammation and colonic integrity with therapeutic benefits in IBD mouse models (IMMUNOLOGY 2025) - "Additionally, the potential benefits of KBL382 were reflected in positive changes in gut microbiome alpha and beta diversities. Collectively, these findings underscore the promising therapeutic potential of Lactobacillus paracasei KBL382 in the treatment of IBD.Keywords: Animals Human; Cells T Cells; Diseases Autoimmunity; Processes Inflammation; Tissues Mucosa"

Late-breaking abstract • Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Kolmar partners with US CDMO to develop microbiome drugs (Korea Biomedical Review) - "Kolmar Holdings said it would partner with the U.S. contract development and manufacturing organization (CDMO) Arranta Bio to develop KBL382, a candidate substance for treating inflammatory bowel disease...Their initial goal is to apply for the global phase 1 clinical trial of an investigational new drug (IND) by the second half of next year."

Licensing / partnership • New P1 trial • Inflammatory Bowel Disease